What is HC Wainwright’s Forecast for ACRS FY2026 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – HC Wainwright lifted their FY2026 earnings estimates for shares of Aclaris Therapeutics in a research note issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.57) per share for the year, up from their prior forecast of ($0.61). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2026 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.51) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%.

A number of other brokerages also recently issued reports on ACRS. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research report on Wednesday, October 28th. Wedbush decreased their price objective on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 28th. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Finally, Canaccord Genuity Group boosted their price target on shares of Aclaris Therapeutics from $10.00 to $13.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $11.33.

Aclaris Therapeutics Stock Down 2.1%

Aclaris Therapeutics stock opened at $4.15 on Wednesday. The stock has a market cap of $580.27 million, a price-to-earnings ratio of -7.16 and a beta of 0.96. The business has a 50-day simple moving average of $4.55 and a 200 day simple moving average of $4.53. Aclaris Therapeutics has a 52 week low of $2.10 and a 52 week high of $6.60.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Aclaris Therapeutics during the 2nd quarter valued at about $53,096,000. Rock Springs Capital Management LP boosted its stake in Aclaris Therapeutics by 0.4% in the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock worth $16,772,000 after buying an additional 18,909 shares in the last quarter. Braidwell LP boosted its stake in Aclaris Therapeutics by 26.1% in the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after buying an additional 443,232 shares in the last quarter. Palo Alto Investors LP bought a new position in Aclaris Therapeutics during the second quarter valued at approximately $8,535,045. Finally, Kalehua Capital Management LLC bought a new position in Aclaris Therapeutics during the first quarter valued at approximately $6,871,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.